1.Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: A Multicenter Cohort Analysis
Jihye LIM ; Ji Hoon KIM ; Ahlim LEE ; Ji Won HAN ; Soon Kyu LEE ; Hyun YANG ; Heechul NAM ; Hae Lim LEE ; Do Seon SONG ; Sung Won LEE ; Hee Yeon KIM ; Jung Hyun KWON ; Chang Wook KIM ; U Im CHANG ; Soon Woo NAM ; Seok-Hwan KIM ; Pil Soo SUNG ; Jeong Won JANG ; Si Hyun BAE ; Jong Young CHOI ; Seung Kew YOON ; Myeong Jun SONG
Gut and Liver 2025;19(3):427-437
Background/Aims:
This study aimed to evaluate the performance of the Model for End-Stage Liver Disease (MELD) 3.0 for predicting mortality and liver-related complications compared with the Child-Pugh classification, albumin-bilirubin (ALBI) grade, the MELD, and the MELD sodium (MELDNa) score.
Methods:
We evaluated a multicenter retrospective cohort of incorporated patients with cirrhosis between 2013 and 2019. We conducted comparisons of the area under the receiver operating characteristic curve (AUROC) of the MELD3.0 and other models for predicting 3-month mortality. Additionally, we assessed the risk of cirrhosis-related complications according to the MELD3.0 score.
Results:
A total of 3,314 patients were included. The mean age was 55.9±11.3 years, and 70.2% of the patients were male. Within the initial 3 months, 220 patients (6.6%) died, and the MELD3.0had the best predictive performance among the tested models, with an AUROC of 0.851, outperforming the Child-Pugh classification, ALBI grade, MELD, and MELDNa. A high MELD3.0score was associated with an increased risk of mortality. Compared with that of the group with a MELD3.0 score <10 points, the adjusted hazard ratio of the group with a score of 10–20 pointswas 2.176, and that for the group with a score of ≥20 points was 4.892. Each 1-point increase inthe MELD3.0 score increased the risk of cirrhosis-related complications by 1.033-fold. The risk of hepatorenal syndrome showed the highest increase, with an adjusted hazard ratio of 1.149, followed by hepatic encephalopathy and ascites.
Conclusions
The MELD3.0 demonstrated robust prognostic performance in predicting mortality in patients with cirrhosis. Moreover, the MELD3.0 score was linked to cirrhosis-related complications, particularly those involving kidney function, such as hepatorenal syndrome and ascites.
2.Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
Joo Hye SONG ; Sung Noh HONG ; Myeong Gyu KIM ; Minjung KIM ; Seong Kyung KIM ; Eun Ran KIM ; Dong Kyung CHANG ; Young-Ho KIM
Gut and Liver 2025;19(3):376-387
Background/Aims:
Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from intravenous (IV) infliximab using real-world data are lacking. We aimed to develop a population PK model of IV and SC infliximab to predict individual infliximab exposure during maintenance therapy.
Methods:
We used data from prospectively collected data on IV and SC infliximab concentrations in patients with inflammatory bowel disease receiving maintenance treatment from February 2020 to December 2022 at Samsung Medical Center. Population PK analysis was conducted by using a two-compartment model with first-order absorption and first-order elimination. Goodness-of-fit plots and visual predictive check were used to evaluate the PK model.
Results:
A total of 2,132 samples from 181 patients (149 Crohn’s disease and 32 ulcerative colitis) were analyzed. We developed an infliximab population PK model using body mass index, albumin, C-reactive protein level, and the anti-drug antibody level and validated its predictive performance.
Conclusions
It may be possible to predict the infliximab trough level of both IV and SC infliximab in patients with inflammatory bowel disease during maintenance treatment by using our model in real-world practice.
3.Factors affecting dry eye syndrome and quality of life among college students in Korea: a cross-sectional study
Mi-Kyoung CHO ; Seonhwa YOON ; Yoojin CHO ; Younhye JUN ; Jiseon CHOI ; Minyoung RYU ; Myeong Jin KIM ; Ga Hyun SUNG
Journal of Korean Biological Nursing Science 2025;27(1):72-84
This study aimed to identify the factors affecting dry eye syndrome and quality of life (QoL) among college students. Methods: This cross-sectional study administered a descriptive survey to 184 college students across Korea. Data collection was conducted from August 27 to 28, 2024, using an online survey platform (Google Forms). The self-reported survey comprised the Health-Related Quality of Life Instrument with 8 Items scale, the Dry Eye Questionnaire 5, and the Ocular Surface Disease Index. Data analysis was performed using SPSS version 27.0. Results: The participants had a mean age of 21.37 (standard deviation 1.96) years. Regression analysis identified sleep satisfaction, vision-related functions, and dry eye symptoms as statistically significant predictors of QoL, accounting for 18.4% of the variance (F = 14.71, p < .001). Dry eye symptoms were significantly influenced by the use of artificial tears, vision-related functions, and environmental factors, which accounted for 41.3% of the variance (F = 43.93, p < .001). Additionally, significant determinants of ocular surface disease included the use of vision correction tools, the presence of ophthalmic diseases, sleep satisfaction, and dry eye symptoms. These factors explained 45.7% of the variance, confirming the model's robustness (F = 31.84, p < .001). Conclusion: It is necessary to identify strategies to alleviate dry eye syndrome in college students and develop comprehensive prevention and management programs to improve their QoL.
4.Factors affecting dry eye syndrome and quality of life among college students in Korea: a cross-sectional study
Mi-Kyoung CHO ; Seonhwa YOON ; Yoojin CHO ; Younhye JUN ; Jiseon CHOI ; Minyoung RYU ; Myeong Jin KIM ; Ga Hyun SUNG
Journal of Korean Biological Nursing Science 2025;27(1):72-84
This study aimed to identify the factors affecting dry eye syndrome and quality of life (QoL) among college students. Methods: This cross-sectional study administered a descriptive survey to 184 college students across Korea. Data collection was conducted from August 27 to 28, 2024, using an online survey platform (Google Forms). The self-reported survey comprised the Health-Related Quality of Life Instrument with 8 Items scale, the Dry Eye Questionnaire 5, and the Ocular Surface Disease Index. Data analysis was performed using SPSS version 27.0. Results: The participants had a mean age of 21.37 (standard deviation 1.96) years. Regression analysis identified sleep satisfaction, vision-related functions, and dry eye symptoms as statistically significant predictors of QoL, accounting for 18.4% of the variance (F = 14.71, p < .001). Dry eye symptoms were significantly influenced by the use of artificial tears, vision-related functions, and environmental factors, which accounted for 41.3% of the variance (F = 43.93, p < .001). Additionally, significant determinants of ocular surface disease included the use of vision correction tools, the presence of ophthalmic diseases, sleep satisfaction, and dry eye symptoms. These factors explained 45.7% of the variance, confirming the model's robustness (F = 31.84, p < .001). Conclusion: It is necessary to identify strategies to alleviate dry eye syndrome in college students and develop comprehensive prevention and management programs to improve their QoL.
5.Palliative Care and Hospice for Heart Failure Patients: Position Statement From the Korean Society of Heart Failure
Seung-Mok LEE ; Hae-Young LEE ; Shin Hye YOO ; Hyun-Jai CHO ; Jong-Chan YOUN ; Seong-Mi PARK ; Jin-Ok JEONG ; Min-Seok KIM ; Chi Young SHIM ; Jin Joo PARK ; Kye Hun KIM ; Eung Ju KIM ; Jeong Hoon YANG ; Jae Yeong CHO ; Sang-Ho JO ; Kyung-Kuk HWANG ; Ju-Hee LEE ; In-Cheol KIM ; Gi Beom KIM ; Jung Hyun CHOI ; Sung-Hee SHIN ; Wook-Jin CHUNG ; Seok-Min KANG ; Myeong Chan CHO ; Dae-Gyun PARK ; Byung-Su YOO
International Journal of Heart Failure 2025;7(1):32-46
Heart failure (HF) is a major cause of mortality and morbidity in South Korea, imposing substantial physical, emotional, and financial burdens on patients and society. Despite the high burden of symptom and complex care needs of HF patients, palliative care and hospice services remain underutilized in South Korea due to cultural, institutional, and knowledge-related barriers. This position statement from the Korean Society of Heart Failure emphasizes the need for integrating palliative and hospice care into HF management to improve quality of life and support holistic care for patients and their families. By clarifying the role of palliative care in HF and proposing practical referral criteria, this position statement aims to bridge the gap between HF and palliative care services in South Korea, ultimately improving patient-centered outcomes and aligning treatment with the goals and values of HF patients.
6.Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: A Multicenter Cohort Analysis
Jihye LIM ; Ji Hoon KIM ; Ahlim LEE ; Ji Won HAN ; Soon Kyu LEE ; Hyun YANG ; Heechul NAM ; Hae Lim LEE ; Do Seon SONG ; Sung Won LEE ; Hee Yeon KIM ; Jung Hyun KWON ; Chang Wook KIM ; U Im CHANG ; Soon Woo NAM ; Seok-Hwan KIM ; Pil Soo SUNG ; Jeong Won JANG ; Si Hyun BAE ; Jong Young CHOI ; Seung Kew YOON ; Myeong Jun SONG
Gut and Liver 2025;19(3):427-437
Background/Aims:
This study aimed to evaluate the performance of the Model for End-Stage Liver Disease (MELD) 3.0 for predicting mortality and liver-related complications compared with the Child-Pugh classification, albumin-bilirubin (ALBI) grade, the MELD, and the MELD sodium (MELDNa) score.
Methods:
We evaluated a multicenter retrospective cohort of incorporated patients with cirrhosis between 2013 and 2019. We conducted comparisons of the area under the receiver operating characteristic curve (AUROC) of the MELD3.0 and other models for predicting 3-month mortality. Additionally, we assessed the risk of cirrhosis-related complications according to the MELD3.0 score.
Results:
A total of 3,314 patients were included. The mean age was 55.9±11.3 years, and 70.2% of the patients were male. Within the initial 3 months, 220 patients (6.6%) died, and the MELD3.0had the best predictive performance among the tested models, with an AUROC of 0.851, outperforming the Child-Pugh classification, ALBI grade, MELD, and MELDNa. A high MELD3.0score was associated with an increased risk of mortality. Compared with that of the group with a MELD3.0 score <10 points, the adjusted hazard ratio of the group with a score of 10–20 pointswas 2.176, and that for the group with a score of ≥20 points was 4.892. Each 1-point increase inthe MELD3.0 score increased the risk of cirrhosis-related complications by 1.033-fold. The risk of hepatorenal syndrome showed the highest increase, with an adjusted hazard ratio of 1.149, followed by hepatic encephalopathy and ascites.
Conclusions
The MELD3.0 demonstrated robust prognostic performance in predicting mortality in patients with cirrhosis. Moreover, the MELD3.0 score was linked to cirrhosis-related complications, particularly those involving kidney function, such as hepatorenal syndrome and ascites.
7.Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
Joo Hye SONG ; Sung Noh HONG ; Myeong Gyu KIM ; Minjung KIM ; Seong Kyung KIM ; Eun Ran KIM ; Dong Kyung CHANG ; Young-Ho KIM
Gut and Liver 2025;19(3):376-387
Background/Aims:
Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from intravenous (IV) infliximab using real-world data are lacking. We aimed to develop a population PK model of IV and SC infliximab to predict individual infliximab exposure during maintenance therapy.
Methods:
We used data from prospectively collected data on IV and SC infliximab concentrations in patients with inflammatory bowel disease receiving maintenance treatment from February 2020 to December 2022 at Samsung Medical Center. Population PK analysis was conducted by using a two-compartment model with first-order absorption and first-order elimination. Goodness-of-fit plots and visual predictive check were used to evaluate the PK model.
Results:
A total of 2,132 samples from 181 patients (149 Crohn’s disease and 32 ulcerative colitis) were analyzed. We developed an infliximab population PK model using body mass index, albumin, C-reactive protein level, and the anti-drug antibody level and validated its predictive performance.
Conclusions
It may be possible to predict the infliximab trough level of both IV and SC infliximab in patients with inflammatory bowel disease during maintenance treatment by using our model in real-world practice.
8.Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: A Multicenter Cohort Analysis
Jihye LIM ; Ji Hoon KIM ; Ahlim LEE ; Ji Won HAN ; Soon Kyu LEE ; Hyun YANG ; Heechul NAM ; Hae Lim LEE ; Do Seon SONG ; Sung Won LEE ; Hee Yeon KIM ; Jung Hyun KWON ; Chang Wook KIM ; U Im CHANG ; Soon Woo NAM ; Seok-Hwan KIM ; Pil Soo SUNG ; Jeong Won JANG ; Si Hyun BAE ; Jong Young CHOI ; Seung Kew YOON ; Myeong Jun SONG
Gut and Liver 2025;19(3):427-437
Background/Aims:
This study aimed to evaluate the performance of the Model for End-Stage Liver Disease (MELD) 3.0 for predicting mortality and liver-related complications compared with the Child-Pugh classification, albumin-bilirubin (ALBI) grade, the MELD, and the MELD sodium (MELDNa) score.
Methods:
We evaluated a multicenter retrospective cohort of incorporated patients with cirrhosis between 2013 and 2019. We conducted comparisons of the area under the receiver operating characteristic curve (AUROC) of the MELD3.0 and other models for predicting 3-month mortality. Additionally, we assessed the risk of cirrhosis-related complications according to the MELD3.0 score.
Results:
A total of 3,314 patients were included. The mean age was 55.9±11.3 years, and 70.2% of the patients were male. Within the initial 3 months, 220 patients (6.6%) died, and the MELD3.0had the best predictive performance among the tested models, with an AUROC of 0.851, outperforming the Child-Pugh classification, ALBI grade, MELD, and MELDNa. A high MELD3.0score was associated with an increased risk of mortality. Compared with that of the group with a MELD3.0 score <10 points, the adjusted hazard ratio of the group with a score of 10–20 pointswas 2.176, and that for the group with a score of ≥20 points was 4.892. Each 1-point increase inthe MELD3.0 score increased the risk of cirrhosis-related complications by 1.033-fold. The risk of hepatorenal syndrome showed the highest increase, with an adjusted hazard ratio of 1.149, followed by hepatic encephalopathy and ascites.
Conclusions
The MELD3.0 demonstrated robust prognostic performance in predicting mortality in patients with cirrhosis. Moreover, the MELD3.0 score was linked to cirrhosis-related complications, particularly those involving kidney function, such as hepatorenal syndrome and ascites.
9.Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
Joo Hye SONG ; Sung Noh HONG ; Myeong Gyu KIM ; Minjung KIM ; Seong Kyung KIM ; Eun Ran KIM ; Dong Kyung CHANG ; Young-Ho KIM
Gut and Liver 2025;19(3):376-387
Background/Aims:
Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from intravenous (IV) infliximab using real-world data are lacking. We aimed to develop a population PK model of IV and SC infliximab to predict individual infliximab exposure during maintenance therapy.
Methods:
We used data from prospectively collected data on IV and SC infliximab concentrations in patients with inflammatory bowel disease receiving maintenance treatment from February 2020 to December 2022 at Samsung Medical Center. Population PK analysis was conducted by using a two-compartment model with first-order absorption and first-order elimination. Goodness-of-fit plots and visual predictive check were used to evaluate the PK model.
Results:
A total of 2,132 samples from 181 patients (149 Crohn’s disease and 32 ulcerative colitis) were analyzed. We developed an infliximab population PK model using body mass index, albumin, C-reactive protein level, and the anti-drug antibody level and validated its predictive performance.
Conclusions
It may be possible to predict the infliximab trough level of both IV and SC infliximab in patients with inflammatory bowel disease during maintenance treatment by using our model in real-world practice.
10.Factors affecting dry eye syndrome and quality of life among college students in Korea: a cross-sectional study
Mi-Kyoung CHO ; Seonhwa YOON ; Yoojin CHO ; Younhye JUN ; Jiseon CHOI ; Minyoung RYU ; Myeong Jin KIM ; Ga Hyun SUNG
Journal of Korean Biological Nursing Science 2025;27(1):72-84
This study aimed to identify the factors affecting dry eye syndrome and quality of life (QoL) among college students. Methods: This cross-sectional study administered a descriptive survey to 184 college students across Korea. Data collection was conducted from August 27 to 28, 2024, using an online survey platform (Google Forms). The self-reported survey comprised the Health-Related Quality of Life Instrument with 8 Items scale, the Dry Eye Questionnaire 5, and the Ocular Surface Disease Index. Data analysis was performed using SPSS version 27.0. Results: The participants had a mean age of 21.37 (standard deviation 1.96) years. Regression analysis identified sleep satisfaction, vision-related functions, and dry eye symptoms as statistically significant predictors of QoL, accounting for 18.4% of the variance (F = 14.71, p < .001). Dry eye symptoms were significantly influenced by the use of artificial tears, vision-related functions, and environmental factors, which accounted for 41.3% of the variance (F = 43.93, p < .001). Additionally, significant determinants of ocular surface disease included the use of vision correction tools, the presence of ophthalmic diseases, sleep satisfaction, and dry eye symptoms. These factors explained 45.7% of the variance, confirming the model's robustness (F = 31.84, p < .001). Conclusion: It is necessary to identify strategies to alleviate dry eye syndrome in college students and develop comprehensive prevention and management programs to improve their QoL.

Result Analysis
Print
Save
E-mail